
Vifor Pharma AG – OTC:GNHAY
Vifor Pharma AG stock price today
Vifor Pharma AG stock price monthly change
Vifor Pharma AG stock price quarterly change
Vifor Pharma AG key metrics
Market Cap | 12.45B |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | N/A |
Revenue | N/A |
EBITDA | N/A |
Income | N/A |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeVifor Pharma AG stock price history
Vifor Pharma AG stock forecast
Vifor Pharma AG financial statements
2018 | 1.58B | 152.4M | 9.62% |
---|---|---|---|
2019 | 1.87B | 159.1M | 8.47% |
2020 | 1.70B | 359.6M | 21.08% |
2021 | 1.82B | 265.4M | 14.55% |
Payout ratio | 0% |
---|
2017 | 1.32% |
---|---|
2018 | 1.75% |
2019 | 1.78% |
2020 | 2.45% |
2021 | 2.05% |
Jun 2020 | 4520000000 | 1.22B | 27.14% |
---|---|---|---|
Dec 2020 | 5211700000 | 1.19B | 22.91% |
Jun 2021 | 4916300000 | 1.15B | 23.46% |
Dec 2021 | 5099600000 | 1.13B | 22.17% |
2018 | 193.8M | -376.1M | 158.6M |
---|---|---|---|
2019 | 524.8M | -132.5M | -238.5M |
2020 | 423.8M | 52.4M | -268.4M |
2021 | 527.4M | -48.8M | -210.9M |
Vifor Pharma AG alternative data
Aug 2023 | 2,200 |
---|---|
Sep 2023 | 2,200 |
Oct 2023 | 2,200 |
Nov 2023 | 2,200 |
Dec 2023 | 2,200 |
Jan 2024 | 2,200 |
Feb 2024 | 2,200 |
Mar 2024 | 2,200 |
Apr 2024 | 2,200 |
May 2024 | 2,200 |
Jun 2024 | 2,200 |
Jul 2024 | 2,200 |
Vifor Pharma AG other data
-
What's the price of Vifor Pharma AG stock today?
One share of Vifor Pharma AG stock can currently be purchased for approximately $38.39.
-
When is Vifor Pharma AG's next earnings date?
Unfortunately, Vifor Pharma AG's (GNHAY) next earnings date is currently unknown.
-
Does Vifor Pharma AG pay dividends?
No, Vifor Pharma AG does not pay dividends.
-
How much money does Vifor Pharma AG make?
Vifor Pharma AG has a market capitalization of 12.45B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 6.98% to 1.82B US dollars.
-
What is Vifor Pharma AG's stock symbol?
Vifor Pharma AG is traded on the OTC under the ticker symbol "GNHAY".
-
What is Vifor Pharma AG's primary industry?
Company operates in the Healthcare sector and Drug Manufacturers—Specialty & Generic industry.
-
How do i buy shares of Vifor Pharma AG?
Shares of Vifor Pharma AG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Vifor Pharma AG have?
As Jul 2024, Vifor Pharma AG employs 2,200 workers.
-
When Vifor Pharma AG went public?
Vifor Pharma AG is publicly traded company for more then 4 years since IPO on 8 Jan 2021.
-
What is Vifor Pharma AG's official website?
The official website for Vifor Pharma AG is viforpharma.com.
-
How can i contact Vifor Pharma AG?
Vifor Pharma AG can be reached via phone at +41 58 851 80 00.
Vifor Pharma AG company profile:

Vifor Pharma AG
viforpharma.comOTC
2,200
Drug Manufacturers—Specialty & Generic
Healthcare
Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally. The company offers Ferinject/Injectafer, a solution of ferric carboxymaltose used for the treatment of iron deficiency and iron deficiency anemia; Maltofer, an oral iron polymaltose complex for infants, children, adolescents, and pregnant woman with iron deficiency; and Mircera, a long-acting erythropoiesis-stimulating agent (ESA) to treat symptomatic anemia associated with the chronic kidney disease (CKD).It also provides Retacrit, a short-acting ESA; Venofer, an intravenous iron sucrose used in the intravenous treatment of iron deficiency; and Velphoro, a non-calcium, iron-based chewable phosphate binder for the treatment of hyperphosphatemia in adults with CKD undergoing dialysis. In addition, the company offers Rayaldee, an orally administered, extended release formulation of calcifediol for the treatment of secondary hyperparathyroidism in patients with CKD; and Veltassa for the treatment of hyperkalemia in CKD and chronic heart failure patients. Further, it develops Vadadustat, an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of altitude on oxygen availability; Avacopan, an orally-administered, highly selective inhibitor of C5aR1 for the treatment of orphan and rare renal diseases;ANG-3777 for the treatment of transplant-associated acute kidney injury; Difelikefalin for the treatment for chronic kidney disease-associated pruritus; and VIT-2763 to treat beta-thalassemia. Vifor Pharma AG has a strategic partnership with Fresenius Kabi and Zeria Pharmaceutical. The company was founded in 1872 and is headquartered in Sankt Gallen, Switzerland. As of August 9, 2022, Vifor Pharma AG operates as a subsidiary of CSL Behring AG.
Sankt Gallen, 9014
:
ISIN: US92674R1023
CUSIP: 363378100